What Is Eptifibatide Approved For? Label Indications, Per the Research

Eptifibatide Is a Specialist-Administered Prescription Medicine

Eptifibatide is a prescription medicine delivered intravenously by clinicians in a hospital setting, including the cardiac catheterisation laboratory, coronary care and critical care units, and other monitored environments where platelet function, bleeding, and haemodynamics can be observed continuously. It is not a self-administered product and it is not something an individual starts, stops, or adjusts outside of specialist supervision. Every question about whether eptifibatide is appropriate in a given case, what alternatives exist, and how it interacts with other anticoagulant or antiplatelet therapy belongs with the prescribing clinician and the treating specialist team. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment decision.

Published overviews of antiplatelet pharmacology placed eptifibatide in the class of intravenous glycoprotein IIb/IIIa receptor antagonists, a group used in acute arterial thrombosis settings rather than for long-term outpatient therapy (PMID 30725747). A review of glycoprotein IIb/IIIa inhibitors in cardiovascular medicine described the same class as parenteral agents used around acute coronary events and coronary intervention (PMID 15030283).

What the Label Covers: Approved Indications

Approved labelling for eptifibatide, marketed as Integrilin, covers two closely related cardiovascular settings that the published literature describes consistently. The first is acute coronary syndrome, specifically unstable angina and non-ST-segment-elevation myocardial infarction, including patients managed medically and those proceeding to coronary intervention. The second is treatment of patients undergoing percutaneous coronary intervention, including those receiving intracoronary stents. A Danish drug profile of eptifibatide described the agent in exactly this acute coronary and interventional context (PMID 11218791), and a cardiovascular review of the class placed the glycoprotein IIb/IIIa inhibitors in the same acute coronary syndrome and percutaneous coronary intervention territory (PMID 15030283).

Indication Summary

A Note on Approval Dates

The verified papers summarised on this page did not record specific regulatory approval dates for eptifibatide. The 2001 drug profile discussed the agent as an established intravenous antiplatelet option in acute coronary care at that time (PMID 11218791), which indicates the product was already in clinical use by the start of that decade, but no exact approval date appears in the cited literature. The current, authoritative statement of approved indications is the prescribing information maintained by the relevant regulator and the dispensing institution, and a prescriber or hospital pharmacist can confirm the wording that applies in a given country.

No Dosing Information on This Page

This page does not provide dosing, preparation, infusion, or administration instructions of any kind. Eptifibatide is prepared and infused by trained hospital staff who weigh renal function, concurrent anticoagulation, procedural timing, and bleeding risk. Published reviews of antiplatelet medications emphasised that this class is used under monitoring rather than by patient-directed self-management (PMID 30725747). Anyone seeking specifics should talk to their prescriber or the hospital pharmacy team rather than to a general educational resource.

Mechanism Described in the Published Literature

Eptifibatide is a cyclic peptide that blocks the platelet glycoprotein IIb/IIIa receptor, also written as integrin alpha-IIb beta-3, which is the final common pathway for platelet aggregation because it binds fibrinogen and von Willebrand factor. A review tracing anti-platelet drugs back to snake venom disintegrins and C-type lectins described eptifibatide as a peptide modelled on barbourin, a disintegrin isolated from snake venom, and explained how that structural template produced selectivity for the platelet integrin (PMID 31137917). A later update on snake venom disintegrins revisited the same lineage and the continuing interest in disintegrin-derived scaffolds for integrin-targeted agents (PMID 37818211).

Laboratory work has used the same receptor biology as a reference point. Researchers who characterised a naphthalenic derivative called ND-1 reported that the compound interfered with the binding of fibrinogen to integrin alpha-IIb beta-3 and reduced thrombus formation in their experimental systems, with glycoprotein IIb/IIIa blockade as the shared mechanistic framework (PMID 28097150). That work was mechanistic pharmacology and did not address approved indications.

Investigational Uses Are Not Approved Indications

Several published investigations examined eptifibatide outside the approved coronary settings. These uses were investigational. They were not approved indications, and the literature summarised below should not be read as expanding the label.

Investigational: Intravenous Adjunct in Acute Ischemic Stroke

The Multi-arm Optimization of Stroke Thrombolysis trial, published in 2024, randomly assigned patients with acute ischemic stroke who had received intravenous thrombolysis to adjunctive intravenous argatroban, adjunctive intravenous eptifibatide, or placebo, and researchers reported that neither adjunctive agent improved the 90-day functional outcome measure compared with placebo and that the trial was stopped for futility (PMID 39231343). A subsequent analysis in Stroke compared locally assessed and centrally adjudicated modified Rankin Scale scores from the same trial and reported on the agreement between the two scoring approaches used in that outcome assessment (PMID 40123511). This stroke adjunct role remained investigational in the cited literature.

Investigational: Laboratory and Microfluidic Thrombosis Models

Eptifibatide and related antiplatelet agents have appeared in engineered laboratory systems built to study clot formation. Researchers described an occlusive thrombosis-on-a-chip microfluidic device designed to investigate the effect of anti-thrombotic drugs under flow conditions (PMID 34523623). Earlier microfluidic work modelled the microvascular occlusion and thrombosis that occur in haematologic diseases, using in vitro flow channels rather than patients (PMID 22156199). These were laboratory platforms, and findings from them do not establish any clinical indication.

Investigational: Perioperative Bridging Discussions

A German review of perioperative management of chronic anticoagulation and antiplatelet therapy discussed how clinicians approach interruption and bridging of antithrombotic treatment around surgery, a context in which short-acting intravenous agents are sometimes discussed (PMID 24892468). Bridging strategies described in that review were not presented as approved indications for eptifibatide, and any perioperative plan is a decision for the surgical, anaesthetic, and cardiology teams involved.

Bleeding and Other Adverse Events: What Studies Report

Published summaries of antiplatelet medications described bleeding as the dominant adverse event class for agents that inhibit platelet function, with risk rising when multiple antithrombotic drugs are combined (PMID 30725747). A review of glycoprotein IIb/IIIa inhibitors in cardiovascular medicine discussed bleeding complications and thrombocytopenia as recognised concerns associated with this intravenous class (PMID 15030283). An earlier drug profile of eptifibatide likewise framed bleeding as the principal safety consideration in acute coronary use (PMID 11218791).

In the stroke setting, the trial of adjunctive intravenous argatroban or eptifibatide after thrombolysis reported safety outcomes alongside its futility result, and the investigators concluded that neither adjunct improved functional outcome in that population (PMID 39231343). Hospital teams monitor platelet counts, access sites, haemoglobin, and neurological status when glycoprotein IIb/IIIa inhibitors are used, and any symptom that could indicate bleeding is a matter for immediate clinical attention rather than self-assessment.

How to Tell an Approved Indication From an Investigational One

• Approved indication: the use appears in the regulator-approved prescribing information for the product, as reflected in the acute coronary syndrome and percutaneous coronary intervention settings described in the cardiovascular literature (PMID 15030283).
• Investigational use: the use was studied in a trial or laboratory model without being added to the approved label, as with the stroke adjunct arm reported in 2024 (PMID 39231343).
• Mechanistic or preclinical work: findings come from cells, microfluidic chips, or chemical analogues, as in the thrombosis-on-a-chip device study (PMID 34523623), and say nothing about approved use.

Questions the Treating Specialist Team Can Answer

1. Which approved indication applies to the situation at hand, and what does the current prescribing information say.
2. How bleeding risk is being assessed and monitored during and after the infusion.
3. How eptifibatide fits alongside other antithrombotic medicines already in use, a pairing that published antiplatelet reviews identified as a key determinant of bleeding risk (PMID 30725747).
4. What alternatives exist within or outside the glycoprotein IIb/IIIa class as described in cardiovascular reviews (PMID 15030283).
5. How any planned procedure or surgery changes the antithrombotic plan, a subject addressed in perioperative bridging literature (PMID 24892468).

What the Cited Literature Does Not Establish

The verified papers summarised here did not establish eptifibatide as an approved treatment for acute ischemic stroke, since the randomised trial in that setting reported no improvement in functional outcome and was stopped for futility (PMID 39231343). They did not establish any outpatient, preventive, or long-term role, and they did not document approval dates. Mechanistic reviews of disintegrin-derived agents described the origin of the molecule and the receptor it targets without defining clinical indications (PMID 37818211). For any individual question about eligibility, timing, or alternatives, the answer comes from the prescribing clinician, not from a summary of published abstracts.

References

• Antiplatelet Medications (StatPearls, 2022)
• From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs (Toxins, 2019)
• Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke (The New England Journal of Medicine, 2024)
• Snake venom disintegrins update: insights about new findings (The Journal of Venomous Animals and Toxins Including Tropical Diseases, 2023)
• [Eptifibatide (Integrilin)] (Ugeskrift for Laeger, 2001)
• An "occlusive thrombosis-on-a-chip" microfluidic device for investigating the effect of anti-thrombotic drugs (Lab on a Chip, 2021)
• [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy] (Deutsche Medizinische Wochenschrift, 2014)
• A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin alphaIIbbeta3 (BioMed Research International, 2016)
• Use of GPIIb/IIIa inhibitors in cardiovascular medicine (Expert Review of Cardiovascular Therapy, 2003)
• In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology (The Journal of Clinical Investigation, 2012)
• Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial (Stroke, 2025)